Key result
DRAVP 2.0 expands the antiviral peptide database by ~159%, enhancing functional annotation and usability.
Its licence doesn't allow us to show a copy here.
Why the study?
Antiviral peptides offer promising therapeutic potential due to diverse antiviral mechanisms and favorable toxicity profiles, but existing resources needed broader coverage, enhanced functional annotation, and emphasis on experimentally validated peptides.
Population
5,688 records of antiviral peptides and proteins (including 3,499 new entries)
Comparison
DRAVP 2.0 vs previous database version and existing resources
Design
Curated and genomically annotated database development
Broadens resources for antiviral peptide discovery; leaves open clinical translation pending validation.
Antiviral peptides (AVPs) offer promising therapeutic potential due to their diverse antiviral mechanisms and favorable toxicity profile. We present DRAVP 2.0, a significantly expanded and carefully curated database comprising 3,499 new entries, making a total of 5,688 records, representing a 159% increase compared to the previous version.The update incorporates sequences from peer-reviewed literature, patent records, clinical trials, and introduces stapled antiviral peptides, synthetically stabilized molecules with enhanced pharmacokinetic properties. DRAVP 2.0 features rich, multidimensional annotations, including genomic origin data (gene identifiers, chromosomal locations), structural information from UniProt and the Protein Data Bank, physicochemical properties, and experimental validation status. This comprehensive annotation framework enables detailed biological contextualization and supports cross-disciplinary studies across virology, structural biology, and genomics. The platform also offers improved usability with advanced search modes, hierarchical browsing by virus family, and an integrated BLAST tool. Regular biweekly updates and rigorous quality control ensure the database remains accurate and current. Compared to existing resources, DRAVP 2.0 provides broader coverage, enhanced functional annotation, and emphasizes experimentally validated peptides. This robust and user-friendly platform accelerates antiviral peptide discovery and therapeutic development, addressing critical needs posed by emerging and drug-resistant viral pathogens. DRAVP is available online at https://dravp.cpu-bioinfor.org/.
No takes yet. Share an insight, caveat, or question.
Nawaz et al. (2026) studied this question. DRAVP 2.0 expanded the antiviral peptide database to 5,688 records, a 159% increase, enhancing functional annotation and usability for antiviral research.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: